Company
Headquarters: London, United Kingdom
Employees: 620
CEO: Mr. Matthew Gline
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $123.2 M |
| EBITDA | $-1,025,345,984 |
| Gross Profit TTM | $48.2 M |
| Profit Margin | 3624.14% |
| Operating Margin | -774.17% |
| Quarterly Revenue Growth | 117.80% |
Roivant Sciences Ltd has the following listings and related stock indices.
Stock: NASDAQ: ROIV